Lonza continues realization of long-term strategic initiatives
Lonza Group announced that the U.S. food and Drug Administration (FDA) has granted approval for a supplemental biologics License Application (sBLA) to Bristol-Myers Squibb Company, which includes the licensing of Lonza Biologics Inc. as their third-party manufacturing partner for the active pharmaceutical ingredient (abatacept) for ORENCIA®.
This manufacturing initiative was designed to support increased production capacity for rheumatoid arthritis indicated ORENCIA® (abatacept), which will enable Bristol-Myers Squibb to meet the anticipated long-term demand.
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.